Waki

Researchers are evaluating the efficacy and safety of talquetamab, a drug given by injection, in adults with relapsed or refractory multiple myeloma who have received at least three prior treatments. This Phase 2 study focuses on participants who may or may not have been exposed to T cell redirection therapies. The goal is to understand how well talquetamab works and its safety profile in this patient group. Participants are divided into five cohorts based on their previous treatments and exposure to T cell redirection therapies. They will receive talquetamab by subcutaneous injection at doses selected from earlier parts of the study. Treatment continues until disease progression, and participants will move into open-label and long-term extension phases to keep receiving the study drug as approved by the sponsor. During the trial, participants will have regular assessments including laboratory tests, safety evaluations, and quality of life questionnaires. Researchers will measure outcomes such as overall response rate, duration of response, progression-free survival, and safety events for up to nearly three years. Participants health and treatment effects will be closely monitored throughout this period.